United Therapeutics Corporation has agreed to acquire SteadyMed for $216m.

United Therapeutics will purchase SteadyMed for $4.46 a share in cash and additional $2.63 a share upon commercialisation of Trevyent. The transaction also includes a payment of $75m towards contingent consideration.

Based in the US, United Therapeutics is a biotechnology company, while SteadyMed is a pharmaceutical company based in Israel.

The acquisition will strengthen United Therapeutics’ product pipeline.

United Therapeutics has appointed Gibson, Dunn & Crutcher and Herzog, Fox & Neeman as legal advisers, while SteadyMed has appointed Cooley and Yigal Arnon & Co. as legal advisers for the transaction.

Wedbush PacGrow Life Sciences has been appointed as financial adviser to SteadyMed.

Par Formulations , a subsidiary of Endo International , has agreed to acquire Wintac .

Par Formulations will acquire Wintac along with property located in Bangalore, India, and the manufacturing plants for $30m.

Wintac will operate as a subsidiary of Par Pharmaceutical , upon completion of the acquisition in the second half of this year.

Based in India, Par Formulations is a contract research and manufacturing services provider.

“Par Formulations, a subsidiary of Endo International, has agreed to acquire Wintac.”

Endo Ventures and Par Pharmaceutical have signed an agreement to acquire Somerset Therapeutics from Mendham Holdings and other sellers.

Par Pharma will acquire the entire interests of Somerset, while Endo Ventures will acquire Somerset’s assets for $160m, as part of the transaction.

Somerset Therapeutics will become part of Par Pharma, upon completion of the acquisition in the second half of this year.

Endo Ventures and Par Pharmaceutical are pharmaceutical companies based in India and subsidiaries of Endo International.

Endo has appointed K&L Gates and Shardul Amarchand Mangaldas & Co as legal advisers for the transaction.

US-based biopharmaceutical company Janssen Biotech has agreed to acquire BeneVir Biopharm from HC2 Holdings, which holds 76% of the former’s equity.

HC2 Holdings will receive an upfront payment of $140m and additional contingent payments of up to $900m from Janssen, as part of the transaction. The total consideration is expected to cross approximately $1bn, upon completion of all milestone payments.

The acquisition will enhance BeneVir’s position in the oncolytic viral immunotherapy field.